Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isotretinoin in Toxic Epidermal Necrolysis
NCT02795143Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in toxic epidermal necrolysis (TEN) comparing Isotretinoin with Placebo (2 arms). Primary endpoint: Number of days of hospitalization at 14 days. Planned start Nov 2016; status: withdrawn.
02
Drugs
isotretinoin
03
Conditions
toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on NCT02795143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795143.